Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 551 - 600 of 3753 results
- Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
- Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.
- Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
- Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion.
- Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
- Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
- "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.
- Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
- Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters.
- Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
- Novel 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxepin derivatives displaying combined norepinephrine reuptake inhibition and 5-HT2A/2C receptor antagonism.
- MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
- Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
- The Ins2Akita mouse as a model of early retinal complications in diabetes.
- Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase.
- Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.
- Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats.
- Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
- Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in rats.
- A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
- Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism.
- Structural bioinformatics-based design of selective, irreversible kinase inhibitors.
- A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes.
- The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
- A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
- DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice.
- Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities.
- Duloxetine vs. placebo in patients with painful diabetic neuropathy.
- Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.
- Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle.
- Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite.
- Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses.
- Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study.
- Novel regulatory roles for protein phosphatase-2A in the islet beta cell.
- Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats.
- Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators.
- Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro.
- The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.
- Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat.
- D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes.
- High-throughput screening of interactions between G protein-coupled receptors and ligands using confocal optics microscopy.
- Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats.
- Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha.
- Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation.
- Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas.
- Stem cell division is regulated by the microRNA pathway.
- A database of recombinant viruses and recombinant viral vectors available from the RIKEN DNA bank.
- Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy.
- Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >